louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03316365: Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease
Official title: Long-term Training Effects of Rhythmic Auditory Stimulation on Gait in Patients With Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Continuous Rhythmic Auditory Stimulation
Intermittent Rhythmic Auditory Stimulation
Lead sponsor: University of Toronto
Sponsor class: OTHER
Collaborators: name: Poudre Valley Health System Fort Collins CO
name: Colorado State University
First posted: 2017-10-20
Enrollment: 60
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Falls are common among patients with Parkinson's Disease (PD) and are the biggest contributors to loss of independent living, long-term institutionalization, and increased mortality.

The purpose of this study was to explore whether an at-home based Rhythmic Auditory Stimulation (RAS) gait training program will decrease the number of falls in persons with PD with a history of falling. We also evaluated changes in clinical and kinematic parameters used to assess fall risk in this population.

Sixty participants diagnosed with idiopathic PD with at least 2 falls in the past 12 months, were randomly allocated into two groups. The experimental group trained daily with RAS for 24 weeks. The control group also trained daily with RAS, but discontinued training between weeks 8 and 16. During treatment patients walked for 30 minutes in a home based environment with metronome-click embedded music. Changes in clinical and kinematic parameters were assessed at baseline, weeks 8, 16, and 24.


Eligibility criteria: Inclusion Criteria:

* Hoehn \& Yahr (HY) stage III or IV
* At least 2 falls in the past 12 months
* Stable antiparkinsonian medication regime
* Ability to ambulate independently for at least 50 m.

Exclusion Criteria:

* Other neurological or orthopedic conditions
* Medically diagnosed hearing loss
* Dementia (Mini Mental Status Exam score \< 24).

Primary outcomes:
measure: Fall Index
timeFrame: Change of the number of fall incidents and severity from baseline assessed by the Fall Index 8 weeks, 16 weeks, and 24 weeks.
Secondary outcomes:
measure: Falls Efficacy Scale (FES)
timeFrame: Change in level of concern about falling from baseline assessed by Fear of the Falling Questionnaire/Short FES-1 at 8 weeks, 16 weeks, and 24 weeks.
measure: Berg Balance Scale (BBS)
timeFrame: Change in balance from baseline assessed by Berg Balance Scale at 8 weeks, 16 weeks, and 24 weeks.
measure: Timed Up and Go (TUG)
timeFrame: Change in balance and function from baseline assessed by Timed Up and Go at 8 weeks, 16 weeks, and 24 weeks.
measure: Gait
timeFrame: Change in gait from baseline at 8 weeks, 16 weeks, and 24 weeks.
Other outcomes:
Locations:
Study officials:
affiliation: University of Toronto
name: Michael Thaut, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06704165: Evaluation of Apical Root Resorption in Dental Deep Bite Correction by Twin Slot Orthodontic Bracket
Official title: Evaluation of Apical Root Resorption in Dental Deep Bite Correction by Twin Slot Orthodontic Bracket; a Clinical Trial Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Volumetric Root Resorption
Keywords: intrusion,root resorption
Lead sponsor: Faculty of Dental Medicine for Girls
Sponsor class: OTHER_GOV
First posted: 2024-11-26
Enrollment: 16
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 23
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Evaluate the possible apical root resorption during deep bite correction by double slot bracket with low level slot versus high level slot using CBCT.

Detailed description: Group (A): Patients will be treated with double slot brackets using low level slot in deep bite correction. Group (B): Patients will be treated with double slot brackets using high level slot in deep bite correction.

Eligibility criteria: Inclusion Criteria:

1. Female patients to avoid any sexual dimorphism which may affect the comparison.
2. Age range from 18 to 23year.
3. Patients with anterior dento alveolar deep bite.
4. Angle class I or class II malocclusion with minimal crowding.
5. Healthy compliant and motivated patient.
6. No missing of any tooth except wisdom teeth

Exclusion Criteria:

* 1. Previous orthodontic treatments. 2. Any systemic or bone diseases. 3. Pregnant and lactating patient. 4. Prosthetic replacement in lower anterior teeth. 5. periodontitis with pocket depth more than 5 mm

Primary outcomes:
measure: Primary Outcome Measure
timeFrame: "through study completion, an average of 1 year".
Secondary outcomes:
measure: Secondary Outcome Measure
timeFrame: "through study completion, an average of 1 year".
Other outcomes:
Locations:
city: Bohira
country: Egypt
facility: Alaa Salama
Study officials:
affiliation: AL Azher university
name: Samir Abdo Ibrahim, professor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04810065: SingStrong: Strong Lungs Through Song - Long COVID-19 Study
Official title: SingStrong: Strong Lungs Through Song
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Long Covid
Keywords: Singing
Disordered breathing
Covid-19
Lead sponsor: University of Limerick
Sponsor class: OTHER
First posted: 2021-03-22
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Evidence is emerging that many individuals who recover from Covid-19 are experiencing a range of residual problems. These include fatigue, pain, reduced exercise tolerance and breathing issues. This study includes participants who are experiencing problems with their lungs such as breathing difficulties, shortness of breath, and/or reduced exercise tolerance. The intervention is a twice weekly singing and breathing retraining intervention conducted over ten weeks. A range of self-report questionnaire measures will evaluate the efficacy of the intervention in addressing these problems. Focus groups and individual interviews will also be used to gather information on the impact and acceptability of the programme.


Eligibility criteria: Inclusion Criteria:

* 18 years of age or older
* Previous clinical diagnosis of Covid-19
* Ongoing issues with any or all of: Shortness of breath, disordered breathing, reduced exercise tolerance
* Good written and spoken English language

Exclusion Criteria:

* Lack of a confirmed Covid-19 diagnosis
* Currently undergoing a similar singing or breathing retraining intervention
* No residual problems from a confirmed case of Covid-19

Primary outcomes:
measure: Covid-19 Yorkshire Rehab Screen (C19YRS)
timeFrame: 12 weeks
Secondary outcomes:
measure: DePaul Symptom Questionnaire - Short Form DSQ - SF
timeFrame: 12 weeks
Other outcomes:
Locations:
city: Limerick
country: Ireland
facility: University of Limerick
Study officials:
affiliation: University of Limerick
name: Roisin Cahalan, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00837265: Balugrastim (Neugranin) in Breast Cancer Participants Receiving Doxorubicin/Docetaxel
Official title: A Randomized Study of Subcutaneously Administered Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor) or Pegfilgrastim in Subjects With Breast Cancer Receiving Myelosuppressive Chemotherapy (Doxorubicin/Docetaxel)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
PHASE3
Conditions: Chemotherapy-induced Neutropenia
Keywords: Breast Cancer Supportive Care Neutropenia
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.
Sponsor class: INDUSTRY
First posted: 2009-02-05
Enrollment: 334
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Determination of the effect of balugrastim on the duration and severity of severe neutropenia.


Eligibility criteria: Inclusion Criteria:

* Breast cancer participants scheduled to receive the AT regimen (doxorubicin/ docetaxel).

Exclusion Criteria:

* Participants may have received no more than 1 prior chemotherapy regimen (including adjuvant therapy if given within the last 12 months).

Primary outcomes:
measure: Duration of Severe Neutropenia in Cycle 1
timeFrame: Cycle 1 (cycle length = 21 days)
Secondary outcomes:
measure: Number of Participants With Febrile Neutropenia
timeFrame: Cycles 1 to 4 (each cycle length = 21 days)
measure: Duration of Severe Neutropenia in Cycles 2, 3, and 4
timeFrame: Cycles 2, 3, and 4 (each cycle length = 21 days)
measure: Time to Absolute Neutrophil Count (ANC) Recovery in Cycles 1, 2, 3, and 4
timeFrame: Cycles 1, 2, 3, and 4
Other outcomes:
Locations:
Study officials:
affiliation: Teva Branded Pharmaceutical Products R&D, Inc.
name: Teva Medical Expert, MD
role: STUDY_DIRECTOR
References:
Clinical trial NCT00380965: Evaluation of the Efficacy of Cesamet™ for the Treatment of Pain in Patients With Chemotherapy-Induced Neuropathy
Official title: A Multicenter Trial Evaluating the Safety and Efficacy of Cesamet™ for the Symptomatic Treatment of Chemotherapy-Induced Neuropathic Pain in Patients With Cancer
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Peripheral Neuropathy
Antineoplastic Combined Chemotherapy Protocols
Keywords: Chemotherapy-induced
neuropathy
cancer
Lead sponsor: NEMA Research, Inc.
Sponsor class: INDUSTRY
First posted: 2006-09-27
Enrollment: 23
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study was designed to evaluate the safety and efficacy of Cesamet™ in controlling pain in subjects experiencing pain due to chemotherapy-induced neuropathic pain in patients with cancer.

Detailed description: To determine the safety and efficacy of Cesamet™ in the symptomatic treatment of chemotherapy-induced neuropathic pain.

This is a phase IV, multicenter, open label of Cesamet™ at 1 mg daily progressing to 2mg BID in subjects with chemotherapy-induced neuropathic pain. This study has two phases: A pretreatment phase and a treatment phase.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with chemotherapy-induced neuropathic pain.
* Chronic daily pain present for at least 2 months.
* On stable analgesic regimen for one month.
* Baseline pain score greater than 40mm on a VAS.

Exclusion Criteria:

* Hypersensitivity to compounds in study drug or similar drugs
* Pregnant or lactating females
* Drug or alcohol abuse
* Unstable medical condition

Primary outcomes:
measure: The Average Pain Score at target site.
Secondary outcomes:
measure: The Worst Pain Score at target site.
measure: The Pain at Night Score at target site.
measure: Quality of Life measures.
measure: Patient satisfaction with treatment.
measure: Safety will be assessed through the collection of AEs and vital signs.
Other outcomes:
Locations:
city: Aventura
country: United States
facility: South Florida Medical Research
state: Florida
city: Naples
country: United States
facility: Naples Anesthesia and Pain Associates
state: Florida
Study officials:
affiliation: NEMA Research, Inc.
name: Joseph V Pergolizzi, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: NEMA Research, Inc.
name: Charlotte A Richmond, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT01913665: The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation
Official title: The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Functional Constipation
Lead sponsor: Eskisehir Osmangazi University
Sponsor class: OTHER
First posted: 2013-08-01
Enrollment: 200
Sex: ALL
Minimum age (years): 4
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The aim of this study is to asses the effect of Bifidobacterium lactis and Inulin on functional constipation in children


Eligibility criteria: Inclusion Criteria:

* children with functional constipation over 3 years age
* below 18 years of age

Exclusion Criteria:

* Chronic gastrointestinal disease,
* hirschsprung disease,
* celiac disease,
* hypothyroids,
* neurological deficit,
* constipation treatment receiving children will be excluded

Primary outcomes:
measure: to compare defecation frequency between baseline and 4 th week of treatment
timeFrame: baseline and 4th week of intervention
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT01255865: Comparison Study of Core Temperature Thermometry Systems
Official title: Deep Tissue Thermometry 510(k) Premarket Notification Trial
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Thermometry Device Comparisons
Keywords: Thermometry
Deep Tissue Temperature
Core Temperature
Body Temperature
Rectal Temperature
Oral Temperature
Lead sponsor: 3M
Sponsor class: INDUSTRY
First posted: 2010-12-08
Enrollment: 111
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: OTHER
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 120 subjects of any racial, gender, or ethnic background in who simultaneous measurments of deep tissue, oral, or rectal temperature can be made

Brief summary: The purpose of this trial is the generation of clinical data required for a 510(k) submission to the FDA.

Detailed description: The purpose of this trial is the generation of clinical data required for a 510(k) submission to the FDA. The trial design reflects elements desired by the FDA. The trial is designed to satisfy the relevant requirements of the FDA Guidance (March 1993) on the content of premarket notification \[510(k)\] submissions for clinical electronic thermometers and ISO/IEC 80601-2-56 Medical electrical equipment - Part 2-56: Particular requirements for basic safety and essential performance of clinical thermometers for body temperature measurement.

Eligibility criteria: Inclusion Criteria:

-

Exclusion Criteria:

* Subjects with skin disruptions on the forehead, dysautonomia, spinal cord injury, or taking barbiturates, thyroid preparations, antipsychotics, or who have had a recent (1wk) immunization

Primary outcomes:
measure: Temperature Agreement in Degrees Celsius.
timeFrame: Upon enrollment
Secondary outcomes:
Other outcomes:
Locations:
city: Cleveland
country: United States
facility: Cleveland Clinic
state: Ohio
Study officials:
affiliation: The Cleveland Clinic
name: Daniel i Sessler, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02011165: An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery
Official title: An Objective Evaluation of Postoperative Positioning in Macular Hole Surgery
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Macular Hole
Keywords: Macular hole
Vitrectomy
Gas tamponade
Vitreomacular traction in danger of macular hole formation
Epiretinal membrane in danger of macular hole formation
Lead sponsor: Helse Stavanger HF
Sponsor class: OTHER_GOV
Collaborators: name: Haukeland University Hospital
First posted: 2013-12-13
Enrollment: 43
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CROSSOVER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients undergoing pars plana vitrectomy for macular hole formation, or conditions as epiretinal menbrane or vitreomacular traction where a macular hole formation is likely.

Brief summary: The macular hole formation takes place in the centre of the retina. A closure of the macular hole is believed to take place if the central retinal area is kept dry in the postoperative period. Therefore the eye is filled with a gas mix and the patients are urged to avoid the supine position in the first postoperative days. The investigators use the "tennis ball technique" where a tennis ball is fastened in the back of the night shirt in order to help patients compliance in avoiding the supine sleeping position. The investigators have developed a positioning measuring device which can measure the extent of supine positioning time. Patients are to sleep two nights with the positioning measuring device, one night with a tennis ball in the back of the night shirt and one night without. Hereby the investigators search new knowledge concerning patients compliance and verification of the "tennis ball technique".


Eligibility criteria: Inclusion Criteria:

* Pars plana vitrectomy for macular hole, vitreomacular traction or epiretinal membrane where intra ocular gas tamponade is used.
* Informed consent

Exclusion Criteria:

* Age less than 18 years

Primary outcomes:
measure: Time in supine sleeping position
timeFrame: Two days
Secondary outcomes:
Other outcomes:
Locations:
city: Bergen
country: Norway
facility: Haukeland University Hospital
city: Stavanger
country: Norway
facility: Stavanger University Hospital, Department of Ophthalmology
Study officials:
affiliation: Helse Stavanger HF
name: Vegard Forsaa, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Forsaa VA, Raeder S, Hashemi LT, Krohn J. Short-term postoperative non-supine positioning versus strict face-down positioning in macular hole surgery. Acta Ophthalmol. 2013 Sep;91(6):547-51. doi: 10.1111/j.1755-3768.2012.02464.x. Epub 2012 Jul 25.
Clinical trial NCT02776865: Does Ultrasound-guided Suprascapular Nerve Block Provide Additional Benefit Over Traditional Rehabilitation Program for Patients With Chronic Shoulder Pain
Official title: Does Ultrasound-guided Suprascapular Nerve Block Provide Additional Benefit
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Suprascapular Nerve Block
Keywords: suprascapular nerve block
Lead sponsor: Taipei Veterans General Hospital, Taiwan
Sponsor class: OTHER_GOV
First posted: 2016-05-18
Enrollment: 60
Sex: ALL
Minimum age (years): 40
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was conducted to compare the efficacy of hydrodilatation with hyaluronic acid under ultrasonographic guidance plus physical therapy (PT) with that of PT alone for treating adhesive capsulitis


Eligibility criteria: Inclusion Criteria:

1. chronic shoulder pain with duration of complaints more than 3 months
2. diagnosis of frozen shoulder or rotator cuff disorder

Exclusion Criteria:

1. other conditions involving the shoulder ( rheumatoid arthritis, Hill-Sachs lesions,osteoporosis, or malignancies in the shoulder region);
2. neurologic deficits affecting shoulder function in normal daily activities;
3. shoulder pain caused by cervical radiculopathy
4. a history of drug allergy to xylocaine
5. pregnancy or lactation;
6. received injection into the affected shoulder during the preceding 3 months

Primary outcomes:
measure: change in constant shoulder score
timeFrame: at 4, 12 wk
Secondary outcomes:
measure: change in pain intensity
timeFrame: at 4, 12 wk
measure: change in Shoulder Pain And disability index
timeFrame: at 6, 12 wk
measure: change in glenohumeral joint range of motion
timeFrame: at 4, 12 wk
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: Taipei veteran general hospital
Study officials:
References:
Clinical trial NCT03407365: Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period
Official title: Clinical Efficacy of A Home-Based Functional Exercise Program in Patients With Patellar Femoral Syndrome Over a 10-Week Period
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Patellar Femoral Syndrome
Lead sponsor: NYU Langone Health
Sponsor class: OTHER
First posted: 2018-01-23
Enrollment: 11
Sex: ALL
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine if a 10 week exercise rehabilitation program decreases anterior knee oain (PFPS) and improves function in patients with patellofemoral pain syndrome (PFPS). Individuals (age 18-50) with PFPS will be recruited to participate in this study to see if a 10 week exercise program focusing in core and hip strengthening, lower extremity strengthening foot intrinsic strengthening can decrease pain and increase function.

Detailed description: Patellofemoral pain syndrome (PFPS) is a very prevalent condition that presents in great number to patients in physician's offices and has a high recurrence rate. Physical therapy and exercise therapy to strengthen the quadriceps is often prescribed, however recurrence is common. It is hypothesized that PFPS patients have core weakness, hip strength abnormalities and neuromuscular control deficits.

Eligibility criteria: Inclusion Criteria:

* Individuals wishing to participate in study voluntarily
* Subjects diagnosed with patella-femoral syndrome. We will ascertain this by asking a few questions, which will not be recorded as they have not been enrolled in the study yet.
* Capable of following and completing a 10 week home exercise program

Exclusion Criteria:

* Individuals with prior knee surgery, tibial plateau fractures, known diagnosis of knee injuries such as meniscus or ligaments tears.
* Individuals unable to participate, i.e. cognitive deficits, weakness or functional deficits to upper extremities.
* Individuals unable to tolerate exercise program

Primary outcomes:
measure: Kujala Scale for Anterior Knee Pain
timeFrame: 10 Weeks
Secondary outcomes:
Other outcomes:
Locations:
city: New York
country: United States
facility: New York University School of Medicine
state: New York
Study officials:
affiliation: NYU Langone Health
name: Wayne Stokes, MD
role: PRINCIPAL_INVESTIGATOR
References: